These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

175 related items for PubMed ID: 38958784

  • 1. Combination of monensin and erlotinib synergistically inhibited the growth and cancer stem cell properties of triple-negative breast cancer by simultaneously inhibiting EGFR and PI3K signaling pathways.
    Fang T, Hu S, Song X, Wang J, Zuo R, Yun S, Jiang S, Guo D.
    Breast Cancer Res Treat; 2024 Sep; 207(2):435-451. PubMed ID: 38958784
    [Abstract] [Full Text] [Related]

  • 2. Ononin inhibits triple-negative breast cancer lung metastasis by targeting the EGFR-mediated PI3K/Akt/mTOR pathway.
    Ganesan K, Xu C, Wu J, Du B, Liu Q, Sui Y, Song C, Zhang J, Tang H, Chen J.
    Sci China Life Sci; 2024 Sep; 67(9):1849-1866. PubMed ID: 38900236
    [Abstract] [Full Text] [Related]

  • 3. The combination of NVP-BKM120 with trastuzumab or RAD001 synergistically inhibits the growth of breast cancer stem cells in vivo.
    Yu F, Zhao J, Hu Y, Zhou Y, Guo R, Bai J, Zhang S, Zhang H, Zhang J.
    Oncol Rep; 2016 Jul; 36(1):356-64. PubMed ID: 27175939
    [Abstract] [Full Text] [Related]

  • 4. Expression of MT4-MMP, EGFR, and RB in Triple-Negative Breast Cancer Strongly Sensitizes Tumors to Erlotinib and Palbociclib Combination Therapy.
    Foidart P, Yip C, Radermacher J, Blacher S, Lienard M, Montero-Ruiz L, Maquoi E, Montaudon E, Château-Joubert S, Collignon J, Coibion M, Jossa V, Marangoni E, Noël A, Sounni NE, Jerusalem G.
    Clin Cancer Res; 2019 Mar 15; 25(6):1838-1850. PubMed ID: 30504427
    [Abstract] [Full Text] [Related]

  • 5. Monensin inhibits cell proliferation and tumor growth of chemo-resistant pancreatic cancer cells by targeting the EGFR signaling pathway.
    Wang X, Wu X, Zhang Z, Ma C, Wu T, Tang S, Zeng Z, Huang S, Gong C, Yuan C, Zhang L, Feng Y, Huang B, Liu W, Zhang B, Shen Y, Luo W, Wang X, Liu B, Lei Y, Ye Z, Zhao L, Cao D, Yang L, Chen X, Haydon RC, Luu HH, Peng B, Liu X, He TC.
    Sci Rep; 2018 Dec 17; 8(1):17914. PubMed ID: 30559409
    [Abstract] [Full Text] [Related]

  • 6. EGFR/Notch Antagonists Enhance the Response to Inhibitors of the PI3K-Akt Pathway by Decreasing Tumor-Initiating Cell Frequency.
    Fu W, Lei C, Yu Y, Liu S, Li T, Lin F, Fan X, Shen Y, Ding M, Tang Y, Ye X, Yang Y, Hu S.
    Clin Cancer Res; 2019 May 01; 25(9):2835-2847. PubMed ID: 30670492
    [Abstract] [Full Text] [Related]

  • 7. KLF4 defines the efficacy of the epidermal growth factor receptor inhibitor, erlotinib, in triple-negative breast cancer cells by repressing the EGFR gene.
    Roberts MS, Anstine LJ, Finke VS, Bryson BL, Webb BM, Weber-Bonk KL, Seachrist DD, Majmudar PR, Keri RA.
    Breast Cancer Res; 2020 Jun 18; 22(1):66. PubMed ID: 32552913
    [Abstract] [Full Text] [Related]

  • 8. Excellent effects and possible mechanisms of action of a new antibody-drug conjugate against EGFR-positive triple-negative breast cancer.
    Zhou DD, Bai WQ, Zhai XT, Sun LP, Zhen YS, Li ZR, Miao QF.
    Mil Med Res; 2021 Dec 09; 8(1):63. PubMed ID: 34879870
    [Abstract] [Full Text] [Related]

  • 9. Cotargeting of epidermal growth factor receptor and PI3K overcomes PI3K-Akt oncogenic dependence in pancreatic ductal adenocarcinoma.
    Wong MH, Xue A, Julovi SM, Pavlakis N, Samra JS, Hugh TJ, Gill AJ, Peters L, Baxter RC, Smith RC.
    Clin Cancer Res; 2014 Aug 01; 20(15):4047-58. PubMed ID: 24895459
    [Abstract] [Full Text] [Related]

  • 10. Kaempferol potentiates the sensitivity of pancreatic cancer cells to erlotinib via inhibition of the PI3K/AKT signaling pathway and epidermal growth factor receptor.
    Zhang Z, Guo Y, Chen M, Chen F, Liu B, Shen C.
    Inflammopharmacology; 2021 Oct 01; 29(5):1587-1601. PubMed ID: 34322786
    [Abstract] [Full Text] [Related]

  • 11. Rhizoma Amorphophalli inhibits TNBC cell proliferation, migration, invasion and metastasis through the PI3K/Akt/mTOR pathway.
    Wu C, Qiu S, Liu P, Ge Y, Gao X.
    J Ethnopharmacol; 2018 Jan 30; 211():89-100. PubMed ID: 28962890
    [Abstract] [Full Text] [Related]

  • 12. Discovery of a natural small-molecule compound that suppresses tumor EMT, stemness and metastasis by inhibiting TGFβ/BMP signaling in triple-negative breast cancer.
    Di L, Liu LJ, Yan YM, Fu R, Li Y, Xu Y, Cheng YX, Wu ZQ.
    J Exp Clin Cancer Res; 2019 Mar 21; 38(1):134. PubMed ID: 30898152
    [Abstract] [Full Text] [Related]

  • 13. In Vitro and In Vivo Synergistic Antitumor Activity of the Combination of BKM120 and Erlotinib in Head and Neck Cancer: Mechanism of Apoptosis and Resistance.
    Anisuzzaman AS, Haque A, Wang D, Rahman MA, Zhang C, Chen Z, Chen ZG, Shin DM, Amin AR.
    Mol Cancer Ther; 2017 Apr 21; 16(4):729-738. PubMed ID: 28119490
    [Abstract] [Full Text] [Related]

  • 14. Sophoraflavanone G suppresses the progression of triple-negative breast cancer via the inactivation of EGFR-PI3K-AKT signaling.
    Cheng W, Liu D, Guo M, Li H, Wang Q.
    Drug Dev Res; 2022 Aug 21; 83(5):1138-1151. PubMed ID: 35426453
    [Abstract] [Full Text] [Related]

  • 15. EGFR inhibition blocks cancer stem cell clustering and lung metastasis of triple negative breast cancer.
    Liu X, Adorno-Cruz V, Chang YF, Jia Y, Kawaguchi M, Dashzeveg NK, Taftaf R, Ramos EK, Schuster EJ, El-Shennawy L, Patel D, Zhang Y, Cristofanilli M, Liu H.
    Theranostics; 2021 Aug 21; 11(13):6632-6643. PubMed ID: 33995681
    [Abstract] [Full Text] [Related]

  • 16. Inhibition of RPTOR overcomes resistance to EGFR inhibition in triple-negative breast cancer cells.
    You KS, Yi YW, Kwak SJ, Seong YS.
    Int J Oncol; 2018 Mar 21; 52(3):828-840. PubMed ID: 29344641
    [Abstract] [Full Text] [Related]

  • 17. JARID2 activation by NFYA promotes stemness of triple-negative breast cancer cells through the PI3K/AKT pathway.
    Li J, Zhang X, Liu X, Ma X, Wang Y, Liu Y.
    Expert Rev Anticancer Ther; 2024 Oct 21; 24(10):1029-1040. PubMed ID: 39254227
    [Abstract] [Full Text] [Related]

  • 18. Monensin inhibits epidermal growth factor receptor trafficking and activation: synergistic cytotoxicity in combination with EGFR inhibitors.
    Dayekh K, Johnson-Obaseki S, Corsten M, Villeneuve PJ, Sekhon HS, Weberpals JI, Dimitroulakos J.
    Mol Cancer Ther; 2014 Nov 21; 13(11):2559-71. PubMed ID: 25189541
    [Abstract] [Full Text] [Related]

  • 19. XS-2, a novel potent dual PI3K/mTOR inhibitor, exhibits high in vitro and in vivo anti-breast cancer activity and low toxicity with the potential to inhibit the invasion and migration of triple-negative breast cancer.
    Xu S, Sun X, Luo L, Yang Y, Guo Q, Tang S, Jiang Z, Li Y, Han J, Gan W, Yang F, Zhang X, Liu Y, Sun C, He J, Liu M, Zuo D, Zhu W, Wu Y.
    Biomed Pharmacother; 2022 Nov 21; 155():113537. PubMed ID: 36113258
    [Abstract] [Full Text] [Related]

  • 20. Targeting breast cancer stem cells in triple-negative breast cancer using a combination of LBH589 and salinomycin.
    Kai M, Kanaya N, Wu SV, Mendez C, Nguyen D, Luu T, Chen S.
    Breast Cancer Res Treat; 2015 Jun 21; 151(2):281-94. PubMed ID: 25904215
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.